Ianalumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | BAFF receptor |
| Clinical data | |
| Other names | VAY736 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ianalumab (INN;[1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.[2][3][4]
This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.[5][6] In June 2023 ianalumab was involved in 22 clinical trials, of which 3 were completed, 14 were ongoing, 1 was planned, and 4 were terminated.[7]
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- ^ "Ianalumab - MorphoSys/Novartis". AdisInsight. Springer Nature Switzerland AG.
- ^ van den Hoogen LL, van Laar JM (February 2020). "Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome". Best Practice & Research. Clinical Rheumatology. 34 (1): 101485. doi:10.1016/j.berh.2020.101485. PMID 32067925.
- ^ Narain S, Berman N, Furie R (November 2020). "Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis". Current Opinion in Rheumatology. 32 (6): 609–616. doi:10.1097/BOR.0000000000000754. PMID 33002950. S2CID 222150641.
- ^ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
- ^ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
- ^ "Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab". Pharmaceutical Technology. 30 June 2023.